DHA pregnancy sales drive Martek sales growth

- Last updated on GMT

Related tags: Infant formula, Docosahexaenoic acid

DHA supplier Martek Biosciences has said growth in its product sales in the second quarter was led by the pregnancy and nursing market, whereas sales in the infant formula category were down on last year.

Martek’s business has largely been dominated by sales of its algae-derived DHA omega-3 ingredient to the infant formula market, where it is used in around 95 percent of infant formula products sold in the United States.

Although this remains by far the largest segment for the company, bringing in $77m in the last three months, sales decreased 1 percent on the equivalent period last year. Sales to the food and beverage market were also down, decreasing 6 percent to just under $3m. Non nutritional product sales decreased 18 percent to just under $1m.

However, overall sales were boosted by the pregnancy and nursing category, which led the non-infant formula sales growth of 18 percent to reach just under $7m. Together with increased animal feed sales, this hiked Martek’s second quarter sales by 3 percent to reach a total of $88m.

Related topics: Manufacturers

Related news

Follow us

Products

View more

Webinars